IP Verse

Vectors For Transgene Expression - EP3060668

The patent EP3060668 was granted to Adaptimmune on Oct 19, 2022. The application was originally filed on Oct 24, 2014 under application number EP14792441A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP3060668

ADAPTIMMUNE
Application Number
EP14792441A
Filing Date
Oct 24, 2014
Status
Patent Maintained As Amended
Sep 16, 2022
Publication Date
Oct 19, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

BISCHOF & PARTNER RECHTSANWALTE PARTNERSCHAFTSGESELLSCHAFT MBBMar 18, 2020MICHALSKI HUTTERMANN & PARTNER PATENTANWALTE MBBADMISSIBLE

Patent Citations (3) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
INTERNATIONAL-SEARCH-REPORTWO2012170911
OPPOSITIONUS6284469
OPPOSITIONWO2012170911

Non-Patent Literature (NPL) Citations (22) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
EXAMINATION- SALMON P ET AL, "High-Level transgene expression in human hematopoietic progenitors and differentiated blood lineages after transduction with improved lentiviral vectors", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, (20001115), vol. 96, no. 10, ISSN 0006-4971, pages 3392 - 3398, XP002951290
EXAMINATION- MITTA B ET AL, "Advanced modular self-inactivating lentiviral expression vectors for multigene interventions in mammalian cells and in vivo transduction", NUCLEIC ACIDS RESEARCH, INFORMATION RETRIEVAL LTD, (20021101), vol. 30, no. 21, doi:10.1093/NAR/GNF112, ISSN 0305-1048, page e113, XP002321925
INTERNATIONAL-SEARCH-REPORT- DUPUY F P ET AL, "Lentiviral transduction of human hematopoietic cells by HIV-1- and SIV-based vectors containing a bicistronic cassette driven by various internal promoters", THE JOURNAL OF GENE MEDICINE, (20050901), vol. 7, no. 9, doi:10.1002/jgm.769, ISSN 1099-498X, pages 1158 - 1171, XP055166269 [X] 1-6,8-14,17-32,34-36 * abstract, materials and methods; figures; discussion; * [Y] 1-36
INTERNATIONAL-SEARCH-REPORT- RAMEZANI A ET AL, "Lentiviral vectors for enhanced gene expression in human hematopoietic cells", MOLECULAR THERAPY, NATURE PUBLISHING GROUP, GB, (20001101), vol. 2, no. 5, doi:10.1006/MTHE.2000.0190, ISSN 1525-0016, pages 458 - 469, XP002307687 [X] 1-6,8-14,18,19,21-32,34-36 * abstract; materials and methods; results; discussion; * [Y] 1-36
INTERNATIONAL-SEARCH-REPORT- REAL G ET AL, "Improvement of lentiviral transfer vectors using cis-acting regulatory elements for increased gene expression", APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, SPRINGER, BERLIN, DE, (20110615), vol. 91, no. 6, doi:10.1007/S00253-011-3392-2, ISSN 1432-0614, pages 1581 - 1591, XP019943607 [X] 1-6,8-14,17-19,21-28 * abstract; figures;material and methods; discussion; * [Y] 1-36
INTERNATIONAL-SEARCH-REPORT- ZANTA-BOUSSIF M A ET AL, "Validation of a mutated PRE sequence allowing high and sustained transgene expression while abrogating WHV-X protein synthesis: application to the gene therapy of WAS", GENE THERAPY, (20090501), vol. 16, no. 5, doi:10.1038/gt.2009.3, ISSN 0969-7128, pages 605 - 619, XP055166280 [X] 1-6,8-14,17-19,21-28 * abstract;figures; materials and methods; discussion; * [Y] 1-36
INTERNATIONAL-SEARCH-REPORT- JOHNSTON J M ET AL, "Generation of an optimized lentiviral vector encoding a high-expression factor VIII transgene for gene therapy of hemophilia A", GENE THERAPY, (20130601), vol. 20, no. 6, doi:10.1038/gt.2012.76, ISSN 0969-7128, pages 607 - 615, XP055166279 [X] 1-6,8-14,18,19,21-32,34-36 * abstract; results; figure 1; discussion; * [Y] 1-36
OPPOSITION- 15 Jun 2011, Real et al., 2011. Appl Microbiol Biotechnol, Vol.91, pp 1581-1591
OPPOSITION- Dupuy et al., 2005, J Gene Medicine, Vol. 7 No. 9, pp 1158-1171, 09 May 2005
OPPOSITION- Durand and Cimarelli, 2011, Viruses. Vol. 3, pp 132-159, 14 Feb 2011
OPPOSITION- Johnston el al., 2013, Gene Therapy, Vol. 20, pp 607-615,20 Sep 2012
OPPOSITION- Liechtenstein T., 2013. Cancers. Vol. 5. pp 815-837,02 Jul 2013
OPPOSITION- Mitta et al., 2002, Nucleic Acids Research, Vol. 30 No. 21, el13,2002
OPPOSITION- Mitzushima and Nagata, Nucleic Acids Research, Vol. 18 No17, p 5322, 1990
OPPOSITION- Ramezani et al., 2000. Molecular Therapy, Vol. 2 No. 5, pp458-469, 23 Oct 2000
OPPOSITION- Salmon P. al., 2000. High-level transgene expression in human hematopoietic progenitors and differentiated blood lineages after transduction with improved lentiviral vectors, Blood, Vol.96 No. 10. pp 3392-3398,15 Nov 2005
OPPOSITION- Schambach el al., 2013, Human Gene Therapy’. Vol 24. pp132-142
OPPOSITION- Schambach, et al. Improving Transcriptional Termination ofSelf-Inactivating Gamma-retroviral and Lentiviral Vectors, 2007,Molecular Therapy. VoL 15 No, 6.1167-1173, 03 Apr 2007
OPPOSITION- Schamback et al., 2006, Gene Therapy, Vol. 13. pp 641 -64515 Dec 2005
OPPOSITION- Serafini et al., 2004, Haematologica, Vol. 89. pp 86-95Jan 2004
OPPOSITION- Zanta-Boussif et al., 2009, Gene Therapy, Vol. 16. pp 605-619,05 Mar 2009
OPPOSITION- Zufferey at at., 1999. Journal of Virology, Vol. 73 No. 4. pp 2886-2892, Apr 1999

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents